Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume 19, Issue 9, Pages 1183-1194
Publisher
Oxford University Press (OUP)
Online
2017-02-15
DOI
10.1093/neuonc/nox027
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Telomere dysfunction and chromothripsis
- (2016) Aurélie Ernst et al. INTERNATIONAL JOURNAL OF CANCER
- Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis
- (2016) Vijay Ramaswamy et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma
- (2016) Maura Massimino et al. NEURO-ONCOLOGY
- Biology and management of ependymomas
- (2016) Jing Wu et al. NEURO-ONCOLOGY
- Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma
- (2016) Asuka Araki et al. Acta Neuropathologica Communications
- Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups
- (2015) Kristian W. Pajtler et al. CANCER CELL
- Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis
- (2015) Sabine Spiegl-Kreinecker et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
- (2015) Quinn T. Ostrom et al. NEURO-ONCOLOGY
- Supratentorial ependymomas of childhood carry C11orf95–RELA fusions leading to pathological activation of the NF-κB signaling pathway
- (2014) Torsten Pietsch et al. ACTA NEUROPATHOLOGICA
- Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing
- (2014) Volker Hovestadt et al. NATURE
- C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma
- (2014) Matthew Parker et al. NATURE
- TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas
- (2014) Matthias Simon et al. NEURO-ONCOLOGY
- Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011
- (2014) Quinn T. Ostrom et al. NEURO-ONCOLOGY
- Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes
- (2013) Bárbara Mesquita et al. BREAST CANCER RESEARCH AND TREATMENT
- Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study
- (2013) Pedro Castelo-Branco et al. LANCET ONCOLOGY
- Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age
- (2013) Daniela Lötsch et al. NEURO-ONCOLOGY
- TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism
- (2013) P. S. Rachakonda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
- (2013) P. J. Killela et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas
- (2012) Catherine Godfraind et al. ACTA NEUROPATHOLOGICA
- Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP)
- (2012) J.-P. Kilday et al. CLINICAL CANCER RESEARCH
- Regulation of the human catalytic subunit of telomerase (hTERT)
- (2012) Michael Daniel et al. GENE
- Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis
- (2012) Piergiorgio Modena et al. NEURO-ONCOLOGY
- Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma
- (2011) Hendrik Witt et al. CANCER CELL
- NF-kappaB p65 modulates the telomerase reverse transcriptase in the HepG2 hepatoma cell line
- (2011) Qing-Ping Zuo et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Molecular Staging of Intracranial Ependymoma in Children and Adults
- (2010) Andrey Korshunov et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of telomerase activity with radio- and chemosensitivity of neuroblastomas
- (2010) Simone Wesbuer et al. Radiation Oncology
- New chemotherapy strategies and biological agents in the treatment of childhood ependymoma
- (2009) Karen D. Wright et al. CHILDS NERVOUS SYSTEM
- Pediatric Ependymoma: Biological Perspectives
- (2009) J.-P. Kilday et al. MOLECULAR CANCER RESEARCH
- Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma
- (2008) U Tabori et al. BRITISH JOURNAL OF CANCER
- Ets2 Maintains hTERT Gene Expression and Breast Cancer Cell Proliferation by Interacting with c-Myc
- (2008) Dakang Xu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma
- (2008) Lee Ridley et al. NEURO-ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started